A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia
Focus Adverse reactions
Acronyms OMNIVERSE
Sponsors Celgene Corporation

Most Recent Events

09 Feb 2024 Status changed from active, no longer recruiting to completed.
31 Oct 2023 Planned primary completion date changed from 24 Jun 2024 to 15 Aug 2024.
15 Jun 2023 Results (n=5 of part 1) assessing the safety/tolerability and efficacy and determine the maximum tolerated dose of Oral-AZA + VEN in patients with AML presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight